CD274 and hepatocellular carcinoma: Some antibodies have been approved for clinical use by the U.S. Food and Drug Administration, including: atezolizumab (Tecentriq; Genentech, Inc.; DES MOINES, IA, USA) for triple negative breast cancer (TNBC), unresectable hepatocellular carcinoma (HCC), and extensive-stage small cell lung cancer; durvalumab (Imfinzi; AstraZeneca UK Limited, London, UK) for locally advanced or metastatic urothelial carcinoma; and avelumab (Bavencio; EMD Serono, Inc., Geneva, Switzerland) for advanced renal cell carcinoma.4–8 Currently, many antibodies against PD-L1 are under development or in clinical trials.